{"prompt": "['MC1575', '16', 'Amendment 2', '3.19b Willing to return to enrolling institution for follow-up (during the Active', 'Monitoring Phase of the study).', '3.19c Ability to complete questionnaire(s) by themselves or with assistance.', '3.2', 'Exclusion Criteria', '3.21', 'Any of the following because this study involves an agent that has known', 'genotoxic, mutagenic and teratogenic effects:', 'Pregnant women', 'Nursing women', 'Men or women of childbearing potential who are unwilling to employ', 'adequate contraception', '3.22', 'Chemotherapy/systemic therapy, radiotherapy, immunotherapy or surgery', '<21 days prior to registration or kinase inhibitor therapy <14 days prior to', 'registration or failure to recover from toxicities (to Grade 1 or below) from', 'treatment.', 'NOTE: Concurrent therapy with octreotide is allowed providing that tumor', 'progression on this therapy has been demonstrated. Concurrent therapy with', 'bisphosphonates (e.g. zoledronic acid) or denosumab is also allowed.', 'NOTE: An unlimited number of prior chemotherapeutic or biologic therapies for', 'malignant pheochromocytoma or paraganglioma is permitted. This includes prior', 'anti-angiogenesis therapies such as tyrosine kinase inhibitors.', '3.23', 'Active or uncontrolled intercurrent illness including, but not limited to, ongoing', 'or active infection, symptomatic congestive heart failure, unstable angina', 'pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would', 'limit compliance with study requirements.', '3.24', 'Receiving any other investigational agent', '3.25', 'Current use of warfarin for any reason.', 'NOTE: If patient can be safely transitioned to another anticoagulant, they may', 'be eligible provided other criteria are satisfied.', '3.26', 'Any of the following:', 'QTc prolongation (defined as a QTc interval >500 msecs)', 'LVEF < institutional LLN', 'frequent ventricular ectopy', 'evidence of ongoing myocardial ischemia', '3.27', 'Receiving any medications or substances with risk of torsades de pointes (see', 'Appendix V for partial list).', 'NOTE: Medications or substances with known Risk of Torsades de Pointes are', 'prohibited. Consult pharmacist for review if needed.', '3.28', 'Known active and/or untreated brain metastases.', '3.29a', 'Known severe allergic or other prohibitive reactions to other tyrosine kinase', 'inhibitors (TKI).', '3.29b', 'Prior treatment with lenvatinib.', '3.29c', 'Any of the following conditions:', 'Active peptic ulcer disease', \"Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other\", 'Protocol Version Date:16Aug2018']['MC1575', '17', 'Amendment 2', 'gastrointestinal conditions which increase the risk of perforation', 'History of new abdominal fistula, gastrointestinal perforation or intra-', 'abdominal abscess 84 days prior to registration', 'NOTE: Enrollment of patients with chronic/canalized fistulous tracts (present', 'for >84 days) is allowed.', 'Serious or non-healing wound, ulcer, or bone fracture', 'History of familial QTc prolongation syndrome', '3.29d Any of the following conditions 6 months prior to registration:', 'Cerebrovascular accident (CVA) or transient ischemic attack (TIA)', 'Serious or unstable cardiac arrhythmia', 'Admission for unstable angina or Myocardial infarction', 'Cardiac angioplasty or stenting', 'Coronary artery bypass graft surgery', 'Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT', 'which has been treated with therapeutic anticoagulation <30 days', 'Arterial thrombosis', 'Symptomatic peripheral vascular disease', '3.29e Other active malignancy 2 years prior to registration.', 'EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.', 'NOTE: If there is a history of prior malignancy, they must not be receiving other', 'specific treatment for their cancer.', 'NOTE: Adjuvant anti-estrogen/hormonal therapy for breast cancer is allowed', 'Protocol Version Date: :16Aug2018']\n\n###\n\n", "completion": "END"}